Medical School

Hematology, Oncology and Transplantation

Department of Medicine

Dan Kaufman, MD, PhD


Academic Title

Professor of Medicine


Medical School
Mayo Medical School
University of Wisconsin Hospital and Clinics, (Internal Medicine)
University of Wisconsin Hospital and Clinics (Hematology/BMT)
Mayo Graduate School

Contact Info


Administrative Contact

E: Barbara Porwit
P: (612) 624-5620
F: (612) 625-6919

Mailing Address

Division of Hematology, Oncology and Transplantation
420 Delaware Street SE, MMC 480
Minneapolis, MN 55455

Bio Statement

Dr. Kaufman is a native of the Twin Cities. He did undergraduate work at Stanford University and then completed an MD and PhD (Immunology) at the Mayo Medical School and Mayo Graduate School in Rochester, MN. He then completed both residency training in Internal Medicine and fellowship training in Hematology at the University of Wisconsin-Madison. Dr. Kaufman joined the faculty at the University of Minnesota in 2002. Dr. Kaufman leads a laboratory in the Stem Cell Institute and Masonic Cancer Center focused on using human stem cells to better understand development of blood cells and related cell types. He is also working to translate new stem cell-based therapies to clinical trials for treatment of cancer, chronic infectious disease, vascular disease, and bone repair.

Areas of Expertise

  • Hematopoiesis (Blood cell development)
  • Stem Cell biology
  • Vascular development
  • Immunology and Immunotherapy

Educational Interests

  • PI on Stem Cell Biology Training Grant

Clinical Activities

  • Blood and Marrow Transplantation
  • Hematologic Malignancies
Research Interests

  • Dr. Kaufman’s research interests focus on hematopoietic, vascular and osteogenic cell development from human pluripotent stem cells. This research uses both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) to define developmental pathways and genetic/cellular mechanisms that mediate production of human blood cells and related cell lineages.
  • The Kaufman lab is working to translate these istudies into clinically applicable conditions suitable for clinical trials. Human ESCs and iPSCs cells offer a unique model to investigate basic developmental biology and serve as a therapeutic cell source to replace or repair cells or tissues damaged by disease or other degenerative processes.

For more information visit the KAUFMAN LAB

Research Projects
  • Research support from National Institute of Health, International Clinical Research Center (St. Anne’s University Hospital, Brno, Czech Republic), Minnesota Partnership for Biotechnology, Minnesota Ovarian Cancer Alliance, William Lawrence & Blanche Hughes Foundation, Bill and Melinda Gates Foundation.

Honors, Awards, Organizations

  • Graduation with Departmental Honors, Stanford University Department of Biological Sciences, 1988
  • American Society of Hematology (ASH) Scholar Award for Junior Faculty-Basic Research. 2004-2006
  • University of Minnesota McKnight Land-Grant Professorship, 2005- 2007 (awarded to most promising junior faculty)
  • American Society for Clinical Investigation (ASCI), elected 2009
  • Andersen Chair in Stem Cell Biology. 2010- present
  • Co-Director, Integrated Center of Cellular Therapy and Regenerative Medicine. International Clinical Research Center, St. Anne’s Hospital. Brno, Czech Republic.

Professional Society Memberships

  • American Association for the Advancement of Science, 1999-present
  • American Society of Hematology, 2000-present
  • American Society for Blood and Marrow Transplantation, 2001-present
  • International Society for Experimental Hematology, 2001-present
  • International Society for Stem Cell Research, 2003- present
  • Minnesota Medical Association, 2005- present
  • American Society for Clinical Investigation (ASCI), 2009- present

Publications (Peer-reviewed):

Accepted for Publication

  1. Zou L, Kidwai FK, Kopher RA, Moti J, Kellum CA, Westendorf JJ, Kaufman DS. “Use of RUNX2 expression to identify osteogenic progenitor cells derived from human embryonic stem cells.” Stem Cell Reports (in press Jan 2015)


  1. Ferrell PI, Xi J, Ma C, Adlakha M, Kaufman DS. “The RUNX1 +24 Enhancer and P1 Promoter Identify a Unique Subpopulation of Hematopoietic Progenitor Cells Derived from Human Pluripotent Stem Cells.” Stem Cells (2014 Dec 27) doi: 10.1002/stem.1940. [Epub ahead of print] PMID: 25546363
  2. Ye L, Chang YH, Xiong Q, Zhang P, Zhang L, Somasundaram P, Lepley M, Swingen C, Su L, Wendel JS, Guo J, Jang A, Rosenbush D, Greder L, Dutton JR, Zhang J, Kamp TJ, Kaufman DS, Ge Y, Zhang J. “Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells.” Cell Stem Cell (2014 Dec 4) 15(6):750-61.
  3. Ferrell P, Hexum MK, Kopher RA, Lepley MA, Gussiaas A, and Kaufman DS. “Functional Assessment of Hematopoietic Niche Cells Derived from Human Embryonic Stem Cells.” Stem Cells and Development (2014). 23:1355-63.
  4. Ni Z, Knorr DA, Bendzick L, Allred J and Kaufman DS. “Suppression of HIV Infection by Nature Killer Cells Derived from Chimeric Receptor CD4ζ Expressing Human Pluripotent Stem Cells.” Stem Cells, (2014). 32:1021-31.
  5. Geller MA, Knorr DA, Hermanson DA, Pribyl L, Bendzick L, McCullar V, Miller JS, and Kaufman DS. “Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.” Cytotherapy. (2013). 15, 1297-1306.
  6. Ran D, Shia W, Lo MC, Fan JB, Knorr DA, Ferrell PI, Ye Z, Yan M, Cheng L, Kaufman DS, and Zhang DE. “RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells.” Blood. (2013). 121(15):2882-90.
  7. Knorr DA, Ni Z, Hexum MK, Bendzick L, Cooper LJN , Lee DA,, Kaufman DS.. “Clinical Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells For Cancer Therapy.” Stem Cells Translational Medicine. (2013). 2:274-83.
  8. Solh M, DeFor TE, Weisdorf DJ, Kaufman DS. “Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse.” Biology of Blood and Marrow Transplantation. (2012). 18: 106-112
  9. Ni Z, Knorr DA, Clouser CL, Southern P, Mansky LM, Park IH, Kaufman DS. “Anti-HIV Activity of Natural Killer Cells Derived From Human Pluripotent Stem Cells.” J. of Virology, (2011). 85:43-50.
  10. Hill K, Obrtlikova P, Alvarez D, King J, Keirstead S, Allred J, Kaufman DS. “Human Embryonic Stem Cell Derived Vascular Progenitor Cells Capable of Endothelial and Smooth Muscle Cell Function.” Exp. Hematology, (2010). 38:246-257.
  11. Gori JL,Tian X, Swanson D, Gunther R, Shultz L, McIvor RS, Kaufman DS. “In vivo selection of human embryonic stem cell-derived cells expressing methotrexate-resistant dihydrofolate reductase.” Gene Therapy, (2010). 17:238-49. (Highlighted on F1000 online review site).
  12. Tian X, Hexum MK, Penchev VR, Taylor RJ, Shultz LD, Kaufman DS. “Bioluminescent imaging demonstrates transplanted human embryonic stem cell-derived CD34+ cells preferentially develop into endothelial cells.” Stem Cells (2009). 27:2675-85.
  13. Woll PS, Grzywacz B, Tian X, Marcus R, Verneris MR, Kaufman DS. “Human embryonic stem cells differentiate into a unique population of natural killer cells with highly potent in vivo anti-tumor activity.” Blood, (2009). 113:6094-6101.
  14. Kaufman DS. “Toward Clinical Therapies Utilizing Hematopoietic Cells Derived from Human Pluripotent Stem Cells.” Blood, (2009). 114:3513-3523.
  15. Martin CH, Woll PS, Zuniga-Pflucker JC, Kaufman DS. “Differences in lymphocyte developmental potential between human embryonic stem cell and umbilical cord blood-derived hematopoietic progenitor cells.” Blood, (2008). 112: 2730-2737. (Highlighted on F1000 online review site).
  16. Woll PS, Morris JK, Painschab MS, Marcus RK, Kohn AD, Biechele TL, Moon RT, Kaufman DS. “Wnt signaling promotes hemato-endothelial cell development from human embryonic stem cells.” Blood. (2008). 111: 122-131.
  17. Wilber A , Linehan JL, Tian X, Woll PS, Morris JK, Belur LR, McIvor RS, Kaufman DS “Use of the Sleeping Beauty Transposon System for Genetic Engineering of Human Embryonic Stem Cell-derived Hematopoietic Cells.” Stem Cells, . (2007). 25; 2919-2927.
  18. Flynn C and Kaufman DS. “Donor Cell Leukemia: Insight into cancer stem cells and the stem cell niche.” Blood (2007). 109: 2688-2692.
  19. Tian, X. Woll PS, Morris JK, Linehan JL, Kaufman DS. “Hematopietic Engraftment of Human Embryonic Stem Cell-Derived Blood Cells is Regulated by Host Innate Immunity.” Stem Cells (2006). 24:1370-80.
  20. Woll PS, Martin CH, Miller JS, Kaufman DS. “Human embryonic stem cell-derived natural killer cells acquire functional receptors and cytolytic activity.” J. of Immunology. (2005). 175: 5095-5103.
  21. Tian X, Morris J, Linehan J, Kaufman DS. “Cytokine requirements differ for stroma and embryoid body-mediated mediated hematopoiesis from human embryonic stem cells.” Experimental Hematology (2004). 32, 1000-1009.
  22. Kaufman DS, Lewis RL,Hanson ET, Auerbach R, Plendl J, Thomson JA. “Functional Endothelial Cells Derived From Rhesus Monkey Embryonic Stem Cells.” Blood, (2004). 103: 1325-1332.
  23. Kaufman DS. Hanson ET, Lewis RL, Auerbach R, Thomson JA. “Hematopoietic colony-forming cells derived from human embryonic stem cells.” Proc. Natl. Acad. Sci. USA. (2001). 98:10716-10721.
  24. Odorico JS, Kaufman DS, Thomson JA. “Multilineage differentiation from human embryonic stem cell lines.” Stem Cells. (2001). 19:193-204.
  • ©2014 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on November 24, 2015